Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma.
Novartis Venture Funds
Pentwater Capital Management
Adage Capital Management|
Fidelity Management & Research Company
Schonfeld Strategic Advisors